Acute Myeloid Leukemia – Landscape & Forecast – Disease Landscape & Forecast (G7)

Acute myeloid leukemia (AML) is associated with poor outcomes and low five-year overall survival rates. Although chemotherapy has long been the mainstay of AML treatment, the recent approval of new drugs, such as Revuforj (revumenib), Komzifti (ziftomenib), and Vanflyta (a second-generation FLT3 inhibitor), indicates a trend toward more-targeted therapies. Moreover, both early- and late-phase pipelines for AML include various drug classes such as menin inhibitors, therapeutic vaccines, antibody-drug conjugates, and CAR T-cell therapies. Despite the recent failures of several drugs in late-phase development, we expect the expansion of existing therapies into additional patient populations and the approval of new treatments to lead to notable growth in the AML drug therapy market.

Questions answered:

• How large are the clinically and commercially relevant drug-treatable AML populations, and how will drug-treatable rates change (if at all) over the 2024-2034 forecast period?
• What is the current treatment landscape for AML? What are the key takeaways from expert interviews?
• What are the most promising therapies in the pipeline, and how will they influence the AML therapy market in the future?
• What are the primary factors driving and limiting the AML market, and how will this market evolve over the forecast period?

Geographies: United States, EU5, Japan.

Primary research: Country-specific interviews with thought-leading hematologist-oncologists. Survey data collected for this and other Clarivate research.

Epidemiology: Diagnosed incidence of AML by country, clinically and market-relevant drug-treatable populations.

Forecast: 10-year, annualized, drug-level sales and patient share of key AML therapies through 2034, segmented by brands / generics and epidemiological subpopulations.

Drug treatments: Coverage of key current and late-phase emerging therapies.

Product description

Disease Landscape & Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:

• Optimize your long-term disease and development strategy.
• Quantify market potential for your pipeline assets and those of your competitors.
• Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.
• Gauge the commercial outlook and impact of key market events.